In a study of adults with obesity and asthma, GLP-1 therapy was associated with fewer asthma exacerbations than other weight-management drugs — 1.7% against 4.0%, a risk ratio of 0.438. Emergency and critical-care use ran 7.1% against 13.0%, and acute respiratory failure 0.7% against 1.8%.
Between the two molecules people actually choose between, nothing separated: matching 8,176 tirzepatide users against 8,176 on semaglutide, exacerbation risk came out at 11.0% against 11.1%, a hazard ratio of 1.00. Both studies are observational, and the first says plainly that causal inference is precluded.
In a study of blood eosinophils, counts fell from a median of 160 to 110 per microliter among 371 adults prescribed semaglutide [3]. The study had no control group and recorded no asthma outcomes.
The studies address two different choices: whether to start a GLP-1 or another weight medication, and whether to choose tirzepatide or semaglutide. For the second choice, the guide to tirzepatide’s price premium compares the cost and weight-loss evidence separately from these respiratory findings.
The class against the alternatives
The first compared adults with obesity and documented asthma who started GLP-1-based therapy against adults who started a different weight-management drug, matched one to one, 2,423 per group, followed for a year. [1] Recorded asthma exacerbations were 1.7% against 4.0% — a risk difference of −2.2 percentage points, 95% CI −3.2 to −1.3, risk ratio 0.438, 95% CI 0.306 to 0.626.
Systemic steroid exposure was 16.4% against 23.1%. Emergency department or critical care use was 7.1% against 13.0%. Acute respiratory failure was 0.7% against 1.8%. Every secondary outcome pointed the same way.
One molecule against the other
The second study asked a narrower question: among people with asthma and type 2 diabetes, does it matter which one you start? [2] After matching, 8,176 patients in each group were followed twelve months. Asthma exacerbation occurred in 11.0% on tirzepatide and 11.1% on semaglutide — a hazard ratio of 1.00, 95% CI 0.91 to 1.10. The finding held across sensitivity and subgroup analyses.
On secondary outcomes, systemic corticosteroid use was the same, hazard ratio 1.01, 95% CI 0.96 to 1.05. Rescue inhaler use was marginally lower on tirzepatide, hazard ratio 0.92, 95% CI 0.88 to 0.96. The study reported this as a secondary outcome [2].
How to read the two studies
The first compared GLP-1 therapy with other weight-management drugs in people with obesity. The second compared tirzepatide and semaglutide in people with type 2 diabetes. Both drew from the TriNetX records network, so they share limitations in how treatment and outcomes were recorded. The studies leave open whether weight change or another factor explains the association [1] [2].
In the injection price comparison, 142 sellers listed prices for both medications as of November 2026. Tirzepatide was a median of $70 more per month. The asthma study found similar exacerbation rates and did not measure whether either treatment was better value.
What this means for asthma care
These findings do not establish either drug as an asthma treatment. The cohort comparison did not systematically assess GLP-1-specific adverse events, and the head-to-head study calls for randomized trials [1] [2].